Prime Capital Investment Advisors LLC Purchases 11,835 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Prime Capital Investment Advisors LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1,852.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,474 shares of the biopharmaceutical company’s stock after buying an additional 11,835 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $7,014,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of REGN. CoreCap Advisors LLC raised its stake in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 21 shares during the period. Parkside Financial Bank & Trust raised its position in shares of Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 21 shares in the last quarter. Independence Bank of Kentucky boosted its stake in shares of Regeneron Pharmaceuticals by 7.7% in the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after buying an additional 22 shares during the period. Finally, Redwood Wealth Management Group LLC grew its position in Regeneron Pharmaceuticals by 4.8% during the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 23 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on REGN. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their target price for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Evercore boosted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $788.57.

Regeneron Pharmaceuticals Trading Up 2.5%

Shares of Regeneron Pharmaceuticals stock opened at $785.51 on Friday. The firm’s 50 day moving average is $757.29 and its 200 day moving average is $657.54. The firm has a market capitalization of $82.56 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.06 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a current ratio of 4.13, a quick ratio of 4.22 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $12.07 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.